Thor Medical ASA
OSE:TRMED
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Thor Medical ASA
Operating Expenses
Thor Medical ASA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Operating Expenses
-kr73.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
30%
|
CAGR 10-Years
-1%
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
Operating Expenses
-kr207.2m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-7%
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Operating Expenses
-kr107m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Operating Expenses
-kr105.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-10%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Operating Expenses
-$28.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Operating Expenses
-kr40m
|
CAGR 3-Years
28%
|
CAGR 5-Years
21%
|
CAGR 10-Years
0%
|
|
Thor Medical ASA
Glance View
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
See Also
What is Thor Medical ASA's Operating Expenses?
Operating Expenses
-73.5m
NOK
Based on the financial report for Dec 31, 2025, Thor Medical ASA's Operating Expenses amounts to -73.5m NOK.
What is Thor Medical ASA's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-1%
Over the last year, the Operating Expenses growth was -921%. The average annual Operating Expenses growth rates for Thor Medical ASA have been 45% over the past three years , 30% over the past five years , and -1% over the past ten years .
